Evidence map›Paper›PMID 25312060›Full record

ArticleBMC medical genetics2014

Mapping the deletion endpoints in individuals with 22q11.2 deletion syndrome by droplet digital PCR.

Vicki J Hwang, Dianna Maar, John Regan, Kathleen Angkustsiri, Tony J Simon, Flora Tassone

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. A cross-comparison of cognitive ability across 8 genomic disorders.Current opinion in genetics & development · 2021
    Review
  7. Article
  8. Review
  9. Advantages of ddPCR in detection ofIntractable & rare diseases research · 2019
    Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Vicki J Hwang
Dianna Maar
John Regan
Kathleen Angkustsiri
Tony J Simon
Flora TassoneDepartment of Biochemistry and Molecular Medicine, UC Davis, 2700 Stockton Blvd, Suite 2102, Sacramento 95817, CA, USA. ftassone@ucdavis.edu.
University of California Davis Medical Center · USBio-Rad (United States) · USUniversity of California, Davis · US

Funding

Visuospatial Cognitive Deficit in Del22q11.2 SyndromeR01HD042974 · NICHD · UNIVERSITY OF CALIFORNIA DAVIS · PI SIMON, TONY J · 2003 to 2013
$4.9M
NICHD NIH HHS R01 HD042974NICHD NIH HHS R01HD042974
6 · The paper itself

Abstract

backgroundChromosome 22q11.2 deletion syndrome (22q11DS) is the most common human microdeletion syndrome and is associated with many cognitive, neurological and psychiatric disorders. The majority of individuals have a 3 Mb deletion while others have a nested 1.5 Mb deletion, but rare atypical deletions have also been described. To date, a study using droplet digital PCR (ddPCR) has not been conducted to systematically map the chromosomal breakpoints in individuals with 22q11DS, which would provide important genotypic insight into the various phenotypes observed in this syndrome.

methodsThis study uses ddPCR to assess copy number (CN) changes within the chromosome 22q11 deletion region and allows the mapping of the deletion endpoints. We used eight TaqMan assays interspersed throughout the deleted region of 22q11.2 to characterize the deleted region of chromosome 22 in 80 individuals known to have 22q11DS by FISH. Ten EvaGreen assays were used for finer mapping of the six identified individuals with 22q11DS atypical deletions and covering different regions of chromosome 22.

resultsddPCR provided non-ambiguous CN measurements across the region, confirmed the presence of the deletion in the individuals screened, and led to the identification of five differently sized and located deletions. The majority of the participants (n = 74) had the large 3 Mb deletions, whereas three had the smaller 1.5 Mb deletions, and the remaining three had an interstitial deletion of different size.

conclusionsThe lower cost, rapid execution and high reliability and specificity provided by ddPCR for CN measurements in the 22q11 region constitutes a significant improvement over the variable CN values generated by other technologies. The ability of the ddPCR approach, to provide a high resolution mapping of deletion endpoints may result in the identification of genes that are haplo-insufficient and play a role in the pathogenesis of 22q11DS. Finally, this methodology can be applied to the characterization of other microdeletions throughout the genome.

Indexed as

Chromosomes, Human, Pair 22AdolescentChildChromosome MappingDiGeorge SyndromeDNA Copy Number VariationsFemaleGene DeletionGenetic Association StudiesHumansIn Situ Hybridization, FluorescenceMalePolymerase Chain Reaction

Identifiers

PMID25312060
PMCPMC4258952
OpenAlexW1971677947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.